IMMUTEP LIMITED — Director's Dealing 2022

Sep 12, 2022

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity IMMUTEP LIMITED (ASX: IMM) ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Frederic Triebel
Date of appointment	13 September 2022

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

7,753,764 Fully Paid Ordinary Shares (IMM)

17,061 American Depository Receipts (IMMP)

900,000 Performance Rights (IMMAM) issued on 3 October 2019, granted under the Employee Incentive Plan (the Plan) approved by shareholders at the 2018 Annual General Meeting. 900,000 Performance Rights are due to vest on 1 October 2022.Vesting is contingent upon Dr Triebel being continuously employed in good standing through the vesting period.

2,700,000 Performance Rights (IMMAM) issued on 1 December 2021, granted under the Employee Incentive Plan (the Plan) approved by shareholders at the 2021 Annual General Meeting. One-third to vest on 1 October 2023; one-third to vest on 1 October 2024 and one-third to vest on 1 October 2025. Vesting is contingent upon Dr Triebel being continuously employed in good standing through the vesting period and meeting KPIs related to the following:

• Medical objectives relating to the clinical trials, regulatory affairs and manufacturing;

• Scientific objectives relating to preclinical development and collaborations with

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

external parties; and

• Investor relations objectives to assist with raising awareness and understanding of the Company’s LAG-3 candidates.

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of Number & class of Securities interest Note: Provide details of the circumstances giving rise to the relevant interest. N/A

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
No. and class of securities towhich interest relates

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002